source
- Sanofi drops pursuit of eczema drug amlitelimab after failed Phase 3 trialsSanofi announced it will no longer seek regulatory approval for amlitelimab, an anti‑OX40 ligand antibody intended for atopic dermatitis, after recent Phase 3 data fell short of expectations. The…
- Scribe Therapeutics launches $129M IPO, kicking off second-half biotech listing spreeScribe Therapeutics, a nine-year-old biotech co-founded by CRISPR pioneer Jennifer Doudna, announced its initial public offering. The company priced the IPO at about $128.7 million, raising roughl…